Thus, we speculated that UTX, which is considered as an oncogene in NSCLC, is expected to be a target for the treatment of some NSCLC cases that lack specific targeting treatment, and the combination of UTX inhibitor and TKIs may have positive effect on EGFR mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.